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P-glycoprotein (P-gp) pumps multiple types of drugs out of the cell, using energy generated from ATP, and confers multidrug
resistance (MDR) on cancer cells. ZD6474 is an orally active, selective inhibitor of the vascular endothelial growth factor receptor,
epidermal growth factor receptor, and rearranged during transfection tyrosine kinases. This study was designed to examine whether
ZD6474 reverses P-gp-mediated MDR in cancer cells. Here, we show that clinically achievable levels of ZD6474 reverse
P-gp-mediated MDR of the P-gp-overexpressing cell lines derived from breast cancer, MCF-7/adriamycin (ADR), and human oral
epidermoid carcinoma, KBV200 to ADR, docetaxel, and vinorelbine. This ability to reverse the P-gp-mediated resistance is
comparable to that of another frequently used reversal agent known as verapamil. ZD6474 itself moderately inhibits the proliferation
of both MCF-7 and MCF-7/ADR cells with almost equal activity, but its inhibitory effect is not altered by co-incubation with verapamil,
suggesting that ZD6474 may not be a substrate of P-gp. In addition, ZD6474 increases the intracellular accumulation of the P-gp
substrate, rhodamine-123, and ADR, by enhancing the uptake and/or decreasing the efflux of these compounds in resistant cells.
Further studies show that ZD6474 stimulates ATPase activity in a dose-dependent manner, which is required for the proper function
of P-gp. In contrast, ZD6474 does not inhibit the expression level of P-gp. Our results suggest that ZD6474 is capable of reversing
MDR in cancer cells by directly inhibiting the function of P-gp, a finding that may have clinical implications for ZD6474.
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Transporter proteins belonging to the ATP-binding cassette (ABC)
superfamily pump out drugs using the energy from ATP hydrolysis
and this leads to resistance of cancer cells to multiple anticancer
drugs (Bates et al, 2001; Borst and Elferink, 2002). ABC
transporters are frequently expressed in tumour tissues, so it is
believed that the overexpression of ABC transporter proteins is a
major mechanism responsible for multidrug resistance (MDR)
(Litman et al, 2001). Among them, P-glycoprotein (P-gp/ABCB1)
plays a key role in mediating MDR (Borst and Elferink, 2002; Doyle
and Ross, 2003).
ZD6474 (Vandetanib; ZACTIMA, AstraZeneca Pharmaceuticals,
Macclesfield, UK) is an oral, small molecule inhibitor of the
vascular endothelial growth factor receptor (VEGFR), epidermal
growth factor receptor (EGFR), and rearranged during transfection
(RET) tyrosine kinases. ZD6474 displays antitumour efficacy by
directly inhibiting tumour cell proliferation and survival via EGFR
and RET inhibition, as well as tumour angiogenesis via VEGFR
inhibition (Ryan and Wedge, 2005). ZD6474 is currently in phase
III clinical trials for the treatment of follicular, medullary,
anaplastic, and locally advanced and metastatic papillary thyroid
cancer, as well as for other cancers including non-small cell lung
cancer.
Multidrug resistance is one of the major causes of failure in
cancer chemotherapy, and numerous efforts have been made to
overcome MDR. The most employed strategy has been to develop
MDR inhibitors including the calcium channel blocker, verapamil
(VPL), and the immunosuppressant, cyclosporine A, which reverse
MDR by functioning as competitive substrates of P-gp. However,
their clinical benefits are limited due to high toxicity at resistance-
inhibiting doses. Another important MDR inhibitor, PSC-833, has
not been successful in clinical trials either. Recent studies have
shown that the tyrosine kinase inhibitors, STI-571 and AG1393,
interact with the human P-gp and human multidrug resistance
protein 1 (ABCC1) (Hegedus et al, 2002), and significantly inhibit
ABC transport activities. Gefitinib, an EGFR inhibitor, reverses
chemotherapy resistance in multidrug-resistant cancer cells
expressing the ABC family of proteins (Yang et al, 2005). These
reports collectively suggest that tyrosine kinase inhibitors may be
promising MDR inhibitors. More importantly, it has been reported
that ZD6474 has synergistic effects with many chemotherapeutic
agents in reducing colony formation in GEO, MCF-10A ras, ZR-75-1,
OVCAR-3, CALU-6, MNK-28, and AGS cancer cell lines grown in
soft agar (Ciardiello et al, 2003) in vitro. In vivo, ZD6474 may
potentiate the efficacy of paclitaxel against established human
gastric carcinoma GEO xenografts (Ciardiello et al, 2003).
Currently, ZD6474 is being clinically tested for its efficacy in
combination with multiple chemotherapeutic agents (Massarelli
and Herbst, 2006). Nevertheless, the mechanism underlying the
ZD6474-mediated chemosensitising effect is still unclear. In this
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sstudy, we examined the effect of ZD6474 on MDR and found that
ZD6474 reverses the P-gp-mediated resistance to adriamycin
(ADR), docetaxel, and vinorelbine (VNR), but increases the
accumulation of P-gp substrates in multidrug-resistant MCF-7/
ADR cells. This is achieved by stimulating the ATPase activity of
P-gp that is expressed on the cell membrane. Our findings suggest
that a combination of ZD6474 with cytotoxic agents may overcome
MDR in clinical settings.
MATERIALS AND METHODS
Materials
Chemicals and reagents ZD6474 was synthesised at the Shanghai
Institute of Materia Medica, Chinese Academy of Sciences, China.
Docetaxel, ADR, and VNR were obtained from Jiangsu Hengrui
Pharmaceutical Co. (Lianyungang, China). Sulforhodamine B,
rhodamine-123 (Rho-123), and VPL were purchased from Sigma
Chemical Co. (St Louis, MO, USA). The antibody to P-gp was
purchased from Alexis Biotechnology Inc. (San Diego, CA, USA).
Cell culture The human breast cancer cells, MCF-7, and their
MDR cell subline MCF-7/ADR were maintained in Dulbecco’s
modified Eagle medium containing 10% heat-inactivated fetal




1 bovine insulin at 371C (5% CO2). The human
oral epidermoid carcinoma cell line, KB, and its MDR cell subline,
KBV200, were maintained in RPMI 1640 medium containing
10% heat-inactivatedFBS, 100kUl
1 penicillin, and 200kUl
1
streptomycin.
Cytotoxicity test Cytotoxicity tests were performed using a
sulforhodamine B assay (Schneider et al, 1994). Briefly, cells were
grown in 96-well plates and various concentrations of drugs were
added to the wells for 72h prior to being assayed. The IC50
(concentration required for 50% inhibition) was calculated by the
Logit method. Fold resistance for individual drugs was defined as
the IC50 of MDR cancer cells divided by that of the parental drug-
sensitive cells.
Drug uptake and efflux assay The assay was performed according
to a previously described method (Ludescher et al, 1991; Wang
et al, 2004; Yang et al, 2005). For the Rho-123 uptake assay, cells
were incubated with 5mM Rho-123, in the presence or absence of
ZD6474, at 371C for 1h. The cells were observed and photographed
under an Olympus fluorescence microscope (Olympus Optical,
Tokyo, Japan) or analysed with a FACSCalibur flow cytometer (BD
Biosciences, San Jose, CA, USA). For the efflux assay, the cells were
incubated in medium containing 1mM ADR for 1h, and then
cultured in ADR-free medium, with or without ZD6474 for
additional 1.5h. Cellular ADR accumulation was then analysed
as described above.
Preparation of cell lysates and western blotting After drug
treatment, cells were washed twice with ice-cold phosphate-
buffered saline (137mM NaCl, 2.7mM KCl, 10mM Na2HPO4,
1.8mM KH2PO4, pH 7.4) and total cell lysates were collected in
sodium dodecyl sulfate (SDS) sample buffer (50mM Tris-HCl, pH
6.8, 100mM dithiothreitol (DTT), 2% SDS, 0.1% bromophenol blue,
10% glycerol). Cell lysates, containing equal amounts of protein,
were separated by SDS–polyacrylamide gel electrophoresis
(PAGE) and transferred to polyvinylidine difluoride membranes.
After being blocked in 5% non-fat milk in Tris-buffered saline
with 0.1% Tween 20 (pH 7.6), membranes were incubated with the
appropriate primary antibodies at 41C, overnight, and exposed to
the appropriate secondary antibody for 3h at room temperature.
Immunoreactive proteins were visualised using the enhanced
chemiluminescence system from Pierce (Rockford, IL, USA).
Measurement of P-gp ATPase activity MCF-7 and MCF-7/ADR
cells were harvested, and their membranes were isolated and
stored at 801C as described previously (Orlowski et al, 1996;
Garrigues et al, 2002). ATPase activity was measured at 371C, with
a coupled enzyme assay, by continuous monitoring of absorbance
at 340nm. In order to maintain constant MgATP concentrations,
the medium consisted of 10mM Tris/HCl, pH 7.8 (at 201C), 100mM
NaCl, 10mM KCl, 2mM MgCl2,1m M DTT, and 1mM MgATP, and
was supplemented with 1mM phosphoenolpyruvate, 0.5mM
nicotinamide adenine dinucleotide, 0.1mgml
1 lactate dehydro-
genase, and 0.1mgml
1 pyruvate kinase. Some membrane
ATPases were inhibited by the addition of 10mM sodium azide,
0.5mM ouabain, and 1mM ethylene glycol tetraacetic acid.
Statistical analysis




P-glycoprotein is overexpressed in MCF-7/ADR and KBV200 cells
(data not shown). The IC50s of ADR for MCF-7 and MCF-7/ADR
cells were 2.0 and 122.8mM, respectively (Figure 1A and B). Thus,
overexpression of P-gp confers MCF-7/ADR cells resistance to
ADR (460-fold resistance). In addition, MCF-7/ADR cells are
simultaneously resistant to docetaxel (data not shown), demon-
strating that MCF-7/ADR cells have an MDR phenotype. ZD6474
did not sensitise MCF-7 cells to ADR (Figure 1A), but significantly
sensitised MCF-7/ADR cells to ADR and docetaxel, as well as
sensitising KBV200 cells to VNR (Figure 1B–D). The chemosensi-
tising ability of ZD6474 was dose dependent (Figure 1B and D).
The IC50s were dramatically decreased by 10mM ZD6474, from
122.8 to 4.1mM for ADR, and from 9.4 to 1.7mM for docetaxel
(Figure 1B and C). ZD6474 (1mM) also caused a decrease in the
IC50 of VNR, from 5.7 to 0.6mM (Figure 1D) in KBV200 cells. Of
note, 10 or 1mM ZD6474 itself had little growth-inhibitory effect on
MCF-7/ADR cells or KBV200 cells, respectively. These results
suggest that ZD6474 is capable of reversing P-pg-mediated MDR
and that this effect is probably mediated via P-gp inhibition.
ZD6474 may not be a substrate of P-gp
ZD6474 itself has an equally moderate inhibitory effect on the
proliferation of both MCF-7 and MCF-7/ADR cells. As shown in
Figure 2A, ZD6474 inhibited the proliferation of MCF-7 and
MCF-7/ADR cells in a dose-dependent manner, with IC50s of 17.3
and 19.3mM, respectively. This was also the case in KB and KBV200
cells where the IC50s were 5.4 and 4.4mM, respectively (Figure 2B).
These data indicate that overexpression of P-gp does not confer
cell resistance to ZD6474, and ZD6474 may not be a substrate of
P-gp. To confirm this, we determined the effect of VPL on ZD6474
in P-gp-overexpressing MCF-7/ADR cells. VPL, a substrate of P-gp,
did not influence the inhibitory effect of ZD6474 in MCF-7/ADR
cells (Figure 2C). These data collectively demonstrate that ZD6474
may not be a substrate of P-gp.
ZD6474 modulates P-gp-mediated uptake and efflux
Reversal of MDR is usually manifested as an increased intracellular
accumulation of chemotherapeutics, which can be achieved by
disturbing P-gp-mediated drug uptake and efflux. Therefore, we
examined the effect of ZD6474 on the uptake and efflux of two
substrates of P-gp, Rho-123, and ADR, in MCF-7/ADR cells.
ZD6474 was shown to increase Rho-123 uptake and decrease ADR
efflux in MCF-7/ADR cells in a dose-dependent manner as
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sdetermined by image analysis (Figure 3A and 4A) and this was
confirmed by flow cytometry analysis (Figure 3B and 4B). The
fluorescent index of Rho-123 was increased from 12.0 to 28.7 by
10mM ZD6474 (Figure 3B). Similarly, the fluorescent index of ADR
was increased from 21.7 to 107.6 by 10mM ZD6474, and to 286.5 by
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Figure 1 ZD6474 reverses P-gp-mediated resistance. P-gp-negative MCF-7 cells or P-gp-positive MCF-7/adriamycin (ADR) and KBV200 cells were
treated with (ADR, docetaxel, or vinorelbine (VNR) in the presence or absence of ZD6474 for different periods of time, and the cell proliferation was
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Figure 2 ZD6474 may not be a substrate of P-gp. (A, B) P-gp-negative MCF-7 and KB cells or P-gp-positive MCF-7/adriamycin (ADR) and KBV200 cells
were exposed to ZD6474 for 72h. (C) MCF-7/ADR cells were treated with ZD6474 in combination with verapamil for 72h. The cell proliferation was
determined by the SRB assay. Each point represents the mean±s.d. for three determinations.
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soverexpress P-gp, ZD6474 had no evident effect on uptake of
Rho-123 nor efflux of ADR. (Figure 3C and 4C).
ZD6474 stimulates P-gp ATPase activity, but does not
affect P-gp expression
The increased accumulation of intracellular drug may be a result
of decreased expression of P-gp or increased activity of P-gp.
Therefore, we examined the effect of ZD6474 on both the
expression and activity of P-gp. As shown in Figure 5A and B,
the expression level of P-gp was not affected by different
treatments with ZD6474. However, ZD6474 significantly increased
the ATPase activity, in a dose-dependent manner, in membranes
of P-gp-overexpressing MCF-7/ADR cells (Figure 5C), but had no
detectable effect on the ATPase activity in MCF-7 membranes,
which do not express P-gp (data not shown).
DISCUSSION
ZD6474 is an oral, small molecule inhibitor of VEGFR, EGFR, and
RET tyrosine kinases. Unlike other chemotherapeutic agents that
readily develop cross-resistance towards other structurally related
or unrelated compounds, both in vitro and in the clinic, ZD6474
has not been reported to develop cross-resistance to prior
chemotherapeutic agents, either in vivo or in vitro (Morelli et al,
2005). In good agreement with these reports, the present study
shows that ZD6474 displays almost equal activity in P-gp-negative
and -positive breast carcinoma and oral epidermoid carcinoma
cells (Figure 2). These results indicate that P-gp does not confer
resistance to ZD6474 in cancer cells and that ZD6474 has no cross-
resistance to classical cytotoxic agents such as ADR, docetaxel, and
venorelbine. This is of clinical significance because it suggests that
ZD6474 may be a good option for patients already developing
MDR.
More importantly, we not only found that ZD6474 may not be a
substrate of P-gp, but that it is also a good inhibitor of MDR. This
is based on the following facts. ZD6474 only increases intracellular
accumulation of Rho-123 and ADR, which are substrates of P-gp,
and sensitises chemotherapeutic agents in cells such as MCF-7/
ADR and KBV200 both of which overexpress P-gp, but not in cells
such as MCF-7 and KB both of which do not express P-gp. More
importantly, ZD6474 stimulates the ATPase activity of P-gp, which
is a key event showing the direct effect of ZD6474 on P-gp. Given
that ZD6474 is a promising anti-cancer agent that is currently
being investigated in clinical trials, the combination of ZD6474
with traditional cytotoxic chemotherapeutics, especially drugs like
ADR, docetaxel, and VNR (to which cancer cells readily develop
MDR), may be a rational and promising strategy for cancer
therapy.
It has been reported that the effects of ZD6474 are synergistic
with those of oxaliplatin and docetaxel in cells which do not
overexpress P-gp, such as KYSE30 esophageal squamous epithelial
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Figure 3 Effect of ZD6474 on the uptake of rhodamine-123 (Rho-123) in MCF-7/ADR cells. (A) MCF-7/ADR cells were incubated with 5mM
rhodamine-123 in the absence (a) or presence of 10mM ZD6474 (b) at 371C for 1h. The cells were observed and photographed under a fluorescence
microscope. (B) Uptake of rhodamine-123 in multidrug-resistant MCF-7/ADR cells was analysed by flow cytometry. (C) ZD6474 had no evident effect on
the rhodamine-123 uptake in MCF-7 cells that do not overexpress P-gp. Data shown are representatives of at least three independent experiments.
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set al, 2005; Troiani et al, 2006). A dose-dependent supra-additive
effect in cell growth inhibition, in vitro, and tumour growth
inhibition, in vivo, was also observed when ZD6474 was used in
combination with paclitaxel or docetaxel (Ciardiello et al, 2003).
Our study shows that sensitivity to chemotherapeutic agents, in
MDR cancer cells, is increased in the presence of clinically relevant
concentrations of ZD6474. However, ZD6474 does not modulate
chemosensitivity in parental chemosensitive cells. These results
seem inconsistent with previous reports (Morelli et al, 2005;
Troiani et al, 2006) and the mechanisms underlying this difference
are currently unclear. However, it is noted in these previous
reports that the ZD6474 treatment schedule is the key aspect for
its combination effect with cytotoxic agents. For example, an
antagonistic effect was observed when cells were pretreated with
ZD6474 followed by cytotoxic agents. On the contrary, a
synergistic effect was evident when cells were pretreated with
cytotoxic agents prior to EGFR antagonists (Morelli et al, 2005;
Troiani et al, 2006). In this study, we treated MCF-7 cells with
ZD6474 and cytotoxic agents simultaneously. Therefore, it is likely
that this treatment schedule lead to the differences observed.
Another reason for the apparent discrepancy between our results
and previous reports may be that we treated cells in culture for
72h, whereas Ciardiello et al (2003) treated cells in soft agar for
10–14 days. Finally, the different cells used in these studies may
also result in different effects of ZD6474 on the cytotoxicity of
chemotherapeutics. These data suggest that the treatment schedule
must be considered when ZD6474 is used in combination with
other cytotoxic agents in the clinic.
Some drug efflux transporters, including P-gp, have an ATP-
binding region. The binding of ATP to the transporter’s
nucleotide-binding site is essential for substrate transport, and
the hydrolysis of ATP by P-gp ATPase is critical for restoring the
transporter to its active conformational state (Rosenberg et al,
2001). Thus, monitoring ATPase activity in cell membrane
preparations, or purified membrane proteins, represents a method
of identifying those compounds that interact with the drug efflux
transporters. P-gp exhibits a highly drug-dependent ATP hydro-
lysis activity, and a variety of P-gp inhibitors, as well as P-gp
substrates, can stimulate ATPase activity (Kerr et al, 2001;
Garrigues et al, 2002; Kitazaki et al, 2005). In addition, in the
ATPase activity assay, a test molecule is concluded to interact
specifically with P-gp if it significantly modulates ATPase activities
by 430%, at any one of the concentrations (0.05–50mM) tested
(Garrigues et al, 2002). ZD6474 was clearly shown to stimulate
ATPase activity, by 430%, in the P-gp-expressing membrane and
this stimulation was dose dependent. This suggests that ZD6474
stimulates transporter ATPase activity by directly interacting with
P-gp. Although ATPase activity is closely associated with the
function of P-gp, an increase in the ATPase activity does not
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Figure 4 Effect of ZD6474 on the efflux of adriamycin (ADR) in MCF-7/ADR cells. (A) MCF-7/ADR cells were incubated with 1mM ADR at 371C for 1h,
then incubated in ADR-free medium without (a) or with 10mM ZD6474 (b) at 371C for an additional 1.5h to allow efflux of ADR. The cells were observed
and photographed under a fluorescence microscope. (B) Efflux of ADR in multidrug-resistant MCF-7/ADR cells was analysed by flow cytometry. (C)
ZD6474 had no evident effect on the ADR efflux in MCF-7 cells that do not overexpress P-gp. Data shown are representatives of at least three independent
experiments.
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sVPL is an MDR reversal agent, but it stimulates the ATPase activity
of P-gp (Garrigues et al, 2002). Another example is the flavonoid
compound, 6-prenylchrysin, which is an inhibitor of ABCG2, but
stimulates the ATPase activity of ABCG2 (Ahmed-Belkacem et al,
2005). Given that the function of P-gp mainly manifests as
pumping drugs out of the cells, and ZD6474 was shown to inhibit
the efflux of substrates of P-gp, such as ADR, it is believed that
ZD6474 reverses MDR by directly inhibiting the function of P-gp.
Tyrosine kinase inhibitors are essentially hydrophobic com-
pounds, which must pass through the cell membrane barrier to
reach their intracellular target molecules. It has been reported that
tyrosine kinase inhibitors such as STI-571, ZD1839, and EKI 785
interact with ABCG2 (Ozvegy-Laczka et al, 2004). This modulatory
property may make tyrosine kinase inhibitors ideal compounds for
use in combination with other anticancer drugs. However, the
interaction between ZD6474, an inhibitor of VEGFR, EGFR, and
RET tyrosine kinases, and ABC transporters has not been explored.
In this study, we show that ZD6474 is capable of reversing P-gp-
mediated MDR by directly inhibiting the function of P-gp. More
importantly, ZD6474 significantly inhibits the function of P-gp at
clinically achievable concentrations (E2.1mM) (Holden et al,
2005). This implies that simultaneous administration of ZD6474
with cytotoxic agents, especially substrates of P-gp such as ADR or
docetaxel, may be of clinical benefit for patients bearing tumours
that have P-gp-mediated MDR.
In conclusion, ZD6474 directly interacts with P-gp and inhibits
the function of P-gp at clinically relevant concentrations, and this
is achieved by stimulation of the P-gp ATPase activity. The ability
of ZD6474 to modulate P-gp makes ZD6474 an ideal agent to
combine with cytotoxic agents and overcome MDR in the clinic.
This strategy is therefore worthy of clinical trial testing for cancer
therapy. In addition, ZD6474 blocks several signal transduction
pathways that utilise VEGR and EGFR. The precise role of tyrosine
kinase receptors in the reversal of P-gp-mediated MDR by ZD6474
warrants further investigation.
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Figure 5 ZD6474 stimulates P-gp ATPase activity, but does not affect
P-gp expression. (A) MCF-7/ADR cells were exposed to ZD6474 for 3h.
(B) MCF7/ADR cells were treated with ZD6474 for different periods of
time. Cell lysates were resolved by SDS–PAGE and immunoblotted with
antibodies specific for P-gp. Data shown are representatives of at least
three independent experiments. (C) P-gp-expressing membranes were
obtained from MCF-7/ADR cells and the ATPase activity was determined as
described in the ‘Materials and methods’ section. Each point represents the
mean±s.d. for three experiments. *Po0.05 vs control by Student’s t-test.
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